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Abstract 
With advances in nanoparticle (NP) synthesis and engineering, nanoscale agents with both 
therapeutic and diagnostic functions have been increasingly exploited for cancer manage-
ment. Herein, we synthesized a new type of zwitterionic polymer-gated Au@TiO2 core-shell 
nanoparticles, which showed that they could selectively target and efficiently eliminate cancer cells 
via photothermal therapy (PTT), photodynamic therapy (PDT), pH/NIR-induced drug release, and 
cationic therapy. 
Methods: In the present study, the multifunctional therapeutic agent [Mn@P(CitAPDMAEMA) 
@Au@TiO2@DOX] was prepared to treat cancer with imaging-guided combination method. 
Firstly, Au@TiO2 core-shell nanoparticles (NPs) were synthesized. Taking advantage of broad and 
strong photoabsorption and reactive oxygen species (ROS) generation, Au@TiO2 core-shell NPs 
facilitated the single light-induced PTT and PDT. Next, a chemotherapy drug doxorubicin (DOX) 
was loaded into Au@TiO2 core-shell NPs. Then, a biocompatible zwitterionic polymer 
P(CitAPDMAEMA) was grafted to improve the hemocompatibility of NPs and prolong the 
circulation time. The polymer also served as a capping or switching material for pH-triggered drug 
release. In addition, the cationic nature of P(CitAPDMAEMA) eased the binding to human cervical 
cancer (HeLa) cells and effectively inhibited their growth in acidic environments (termed cationic 
therapy). Moreover, with Mn2+ ions immanently chelated, Mn@P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs were able to provide enhanced contrast under T1- or T2-weighted magnetic resonance 
imaging (MRI).  
Results: The in vitro and in vivo anticancer experiments demonstrated the tumor was effectively 
inhibited with minimal side effects by the multifunctional NPs.  
Conclusions: As far as we know, this is the first presentation of four therapeutic methods into one 
nanomaterial, which will open up a new dimension for the design of combined treatment. 
Key words: Au@TiO2 core-shell NPs, photothermal, photodynamic, cationic therapy, chemotherapy, magnetic 
resonance imaging 
Introduction 
Traditional cancer treatment such as chemo-
therapy can lead to serious side effects, as the 
anticancer drugs kill both cancerous and normal cells 
due to the lack of cell specificity [1-5]. In the last few 
years, nanomaterial-based therapeutic methods such 
as photothermal therapy (PTT), photodynamic 
therapy (PDT) and controlled drug delivery system 
have attracted a lot of attention. PTT ablates 
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malignant tissues by utilizing external light-induced 
hyperthermia. It causes negligible damage to normal 
tissues, and is convenient, non-invasive, remote- 
controllable and safe [6-8]. Various photothermal 
agents such as Au nanoparticles (AuNPs) [9], copper 
NPs [10], carbon derivatives [11], transition metal 
sulfides [12], black titania [13], and black phosphorus 
(BPs) [14] have been intensively explored. Among 
them, AuNPs are preferred due to their high 
absorption ability in the near-infrared (NIR) region 
and excellent biocompatibility [9]. However, for 
AuNPs to be good PTT agents, their localized surface 
plasmon resonance (LSPR) absorption must be tuned 
to the 550-900 nm region to allow for NIR laser 
treatment. This could be done by carefully controlling 
the size and shape of AuNPs, but the synthesis 
process was complicated. Alternatively, the LSPR 
coupling between AuNPs and semiconductor has 
been proposed as a novel approach [15]. Interestingly, 
we found that the titania (TiO2) shell modified with 
AuNPs is one of the most effective methods to shift 
their LSPR absorption to a longer wavelength. The 
condensed free-space optical field within the 
sub-wavelength regions adjacent to the surface of the 
AuNPs enables significant electric field enhancement 
under resonant excitation, which increases the 
efficiency of photothermal conversion. 
On the other hand, PDT relies on photo-
sensitizers (PSs) to release the reactive oxygen 
species (ROS) and cytotoxic free radicals when they 
absorb light at appropriate wavelengths [16-18]. 
Organic PSs are the most widely used PS types. They 
mainly release singlet oxygen (1O2) which is produced 
by spin inversion of triplet oxygen to singlet oxygen 
(type II PDT). Some special organic PSs can also form 
hydrogen peroxide (H2O2) and hydroxyl radicals 
(·OH) by ionization events (type I PDT) [19,20]. 
Despite these advantages, the organic PSs depend on 
oxygen for cytotoxic ROS production, which limits 
PDT effectiveness in hypoxic conditions, such as 
many solid tumors [21]. Moreover, in-situ oxygen in 
PDT is rapidly depleted, creating transient hypoxia 
microenvironment, which further reduces the 
therapeutic effects [22]. Consequently, it is necessary 
to design simple and biocompatible PSs that can 
evolve oxygen continuously without exogenous 
activation [23]. The semiconductor material TiO2 has 
been considered as a new type of PS, as they are able 
to catalyze H2O2 into O2. It is reported that H2O2 is 
abundant in cancer microenvironment and is an 
appropriate source for the production of O2 within 
tumors. However, the application of TiO2 as PSs has 
been hampered by the requirement of UV light 
excitation and the low quantum efficiency [24]. In this 
study, we innovatively combined TiO2 with AuNPs to 
create a novel Au@TiO2 core-shell nanohybrid. 
Coupling TiO2 with AuNPs results in enhanced 
electron-hole separation under red light irradiation, 
which enables the utilization of PTT and PDT for 
cancer treatment at NIR region. 
The in vivo applications of NPs are often 
hindered by the challenges such as short circulation 
time, and biological protein adsorption. One effective 
way to address these problems is to coat the NPs with 
appropriate polymers. Recently, zwitterionic 
polymers have attracted a lot of attention as stealth 
materials in drug delivery systems. Conjugates of 
zwitterionic polymers with therapeutic agents (i.e. 
PSs, drugs or proteins) have been demonstrated [25, 
26]. Due to their limited interactions with biological 
proteins [27, 28], they showed excellent biocompati-
bility and could escape from the reticuloendothelial 
system, achieving long circulation time [30, 31]. We 
synthesized a pH-sensitive polymer with quaternary 
ammonium groups according to a previous method 
[32], which was zwitterionic at physiological pH and 
was converted to a cationic species in acidic 
environments. Herein, we loaded doxorubicin (DOX) 
into the Au@TiO2 core-shell, then grafted the 
zwitterionic polymer onto the NP for combined 
cancer therapy. As the cancer cells’ metabolism and 
the immune response contribute to an acidity tumor 
microenvironment [33, 34], the zwitterionic polymers 
convert to a cationic state when in proximity of the 
tumor tissues. The cationic nature of the polymer, not 
only enhances cellular uptake due to the strengthened 
NP-cellular membrane interactions, but also inhibits 
the cell growth. In addition, the pH-sensitive 
charge-conversion results in the falling of the polymer 
chains, making it possible for “on-demand” drug 
release at the acidic tumor sites. 
In the present study, a novel, multifunctional 
DOX-loaded, manganese ion (Mn2+)-chelated com-
plex, and zwitterionic polymer [P(CitAPDMAEMA)]- 
grafted Au@TiO2 ore-shell NPs [Mn@P(CitAPDMAE 
MA)@Au@TiO2@DOX] was reported, which could 
selectively target and eliminate cancer cells via PTT, 
PDT, pH/NIR-induced drug release and cationic 
therapy (Scheme 1). We have synthesized a new 
Au@TiO2 core-shell through in-situ growth and the 
Ostwald ripening process of TiO2 shells on the 
preformed AuNPs (Scheme 1A). The DOX as a 
chemotherapeutic agent was loaded to the Au@TiO2 
core-shell NPs, which was then coated by the 
zwitterionic polymer P(CitAPDMAEMA) (Scheme 
1B). We also chelated Mn2+ to offer an obvious 
contrast in T1-weighted MRI. The synergetic cancer 
therapy could be achieved under 635 nm laser 
irradiation (Scheme 1C). Au@TiO2 core-shell NPs had 
both photothermal and photodynamic effects with 
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high ROS generating efficiency and photothermal 
conversion efficiency. The Au@TiO2 core-shell NPs 
exhibited improved photodynamic performance 
compared to those of commercial TiO2, Au/TiO2 
hybrid, or Au@TiO2 core-shell NPs. The 
biocompatible P(CitAPDMAEMA) improved the 
hemocompatibility of the NPs. Meanwhile, the 
cationic nature of P(CitAPDMAEMA) facilitated the 
binding to human cervical cancer (HeLa) cells and 
inhibited their growth effectively in an acidic 
environment (Scheme S1). P(CitAPDMAEMA) also 
served as capping or switching materials for 
Au@TiO2@DOX NPs. The drug was only released 
when the NPs reached the low pH environment and 
red light irradiation. In vitro and in vivo studies 
demonstrated that the Mn@P(CitAPDMAEMA)@Au 
@TiO2@DOX NPs could be used as superior 
theranostic agents for multimodality image-guided 
synergistic cancer therapy. 
Results and Discussion 
Preparation and Characterization of Au@TiO2 
Core-shell NPs 
The Au@TiO2 core-shell NPs were prepared 
according to previous methods with some modiﬁca-
tion [35]. The overall procedure is shown in Scheme 
S2. The micro-morphology of the AuNPs (Figure S1A) 
and Au@TiO2 core-shell NPs (Figure S1B) were 
studied by transmission electron microscopy (TEM). 
Figure 1A shows the high-resolution TEM (HR-TEM) 
images of Au@TiO2 core-shell NPs. Due to the 
differential electron densities of Au and TiO2, the 
darker spots were the Au core while lighter areas 
were TiO2 shells. It is worth noting that AuNPs were 
surrounded by a TiO2 shell. Furthermore, the hollow 
space between the core and the shell in each 
nanohybrid could be observed clearly. The Au core 
could move within the TiO2 shell, producing an 
eccentric shape of the Au@TiO2 core-shell NPs. The 
Au@TiO2 core-shell NPs exhibited a uniform diameter 
of 108 nm (Figure S2A), with an average Au core size 
of 30 ± 1.7 nm and an average TiO2 shell thickness of 
32 ± 3.5 nm. The dynamic light scattering (DLS) 
results indicated that the average hydrodynamic 
particle size of Au@TiO2 core-shell NPs was 135 ± 3.8 
nm (Figure S2B), revealing that they were stable 
in deionized water without aggregation. HR-TEM 
images revealed that the TiO2 shell was poly-
crystalline with many small and randomly oriented 
crystallites. The lattice fringes with a d-spacing of 0.23 
nm could be indexed to the (111) plane of Au (Figure 
1B), whereas the d-spacing of 0.35 nm agreed with the 
(101) plane of TiO2 [35]. Moreover, Energy-dispersive 
X-ray (EDS) elemental mapping was also applied to 
characterize the functionalization of Au@TiO2 
core-shell NPs. Figure 1C shows the uniform 
elemental distribution (Ti, Au, and O). The Ti element 
mapping was derived from the TiO2 layer and the Au 
element mapping, suggesting the existence of AuNPs. 
 
 
Scheme 1. Schematic illustration of the synthesis process of the (A) Au@TiO2 core-shell NPs and (B) P(CitAPDMAEMA)@Au@TiO2@DOX. (C) Schematic representation 
of P(CitAPDMAEMA)@Au@TiO2@DOX-based delivery system enhancing the cationic therapy, chemotherapy, PDT, and PTT under red-light irradiation. 
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Figure 1. (A) TEM and (B) HRTEM images of Au@TiO2 core-shell NPs. (C) STEM image and corresponding two-dimensional elemental maps of Au@TiO2 core-shell NPs. (D) 
XPS survey scan for AuNPs and Au@TiO2 core-shell NPs. (E) XRD spectra of AuNPs and Au@TiO2 core-shell NPs. (F) N2 adsorption-desorption isotherms and pore size 
distribution (inset) of Au@TiO2 core-shell NPs. 
 
The components of the Au@TiO2 core-shell 
structure were studied by X-ray photoelectron 
spectroscopy (XPS). Figure 1D shows that the Au 4f 
doublet peaks appeared at 83.3 and 86.9 eV [35], 
where the splitting of 4.5 eV further indicated the 
metallic nature of Au (Figure S3A). The Ti 2p peaks 
for TiO2 were located at about 458.4 and 464.2 eV with 
the splitting of the 2p doublet being at 5.8 eV (Figure 
1D and Figure S3B), confirming a Ti4+ state in 
octahedral coordination with oxygen [36]. The XPS 
spectra peak of O 1 s at 532.1 eV was attributed to the 
Ti-O bonds in the TiO2 lattice (Figure S3C). In 
addition, X-ray diffraction (XRD) was used to study 
two different crystal nanostructures. Figure 1E shows 
that all the samples displayed two series of peaks, 
which belongs to the anatase-TiO2 structure and the 
face-centered-cubic Au. The peaks at 2θ of 25.3, 47.9, 
53.8, and 54.7 could be ascribed to the (101), (200), 
(105), and (211) planes of anatase-TiO2 [37], 
respectively, while the left peaks were corresponding 
to the (111), (200), (220), and (311) faces of 
face-centered-cubic Au. Thus, the presence of Au and 
TiO2 in the Au@TiO2 core-shell NPs were confirmed.  
Nitrogen physisorption measurements were also 
used to study the properties of the Au@TiO2 
core-shell NPs structure. Figure 1F displays the N2 
adsorption-desorption isotherms and the respective 
pore size distribution curves of samples. The 
Au@TiO2 core-shell NPs displayed a type IV isotherm 
with a well-defined hysteresis loop, which indicated 
well-developed mesoporous characteristics. The BET 
surface areas of the Au@TiO2 core-shell NPs were 
estimated to be 50.62 m2/g, and its average pore 
diameters were about 8.96 nm, indicating that the 
Au@TiO2 core-shell NPs could provide more active 
sites and easier passage for the drug into the shell.  
Drug Loading 
In this study, we selected DOX as the model 
drug to test the feasibility of Au@TiO2 core-shell NPs 
as a drug delivery carrier. The conjugation was 
confirmed by zeta potential, UV-vis spectra and 
fluorescence spectra [38]. The zeta potential of 
Au@TiO2 core-shell NPs changed from −18.9 to −1.2 
mV (Figure S4A-B) after DOX loading, indicating that 
the negatively charged Au@TiO2 core-shell NPs 
bonded with positively charged DOX (Figure S4C). A 
notable difference of Au@TiO2@DOX core-shell NPs 
was found in the spectra where the UV-vis absorption 
peak located at 490 nm (Figure 2A). It was caused by 
the absorption of DOX. Moreover, the fluorescence of 
DOX was quenched after DOX loading on the 
Au@TiO2 core-shell NPs (Figure 2B), verifying an 
interaction between the two components. By 
increasing the weight ratio (feeding DOX/Au@TiO2 
core-shell NPs), the drug loaded on the NPs also 
increased (Figure 2C). The maximum loading capacity 
reached ~120%. There are two factors contributing to 
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the high drug-loading capacity of the Au@TiO2 
core-shell NPs. One is that, the Au@TiO2 core-shell 
NPs could bind to DOX molecules via different types 
of interactions, such as electrostatic attraction and 
hydrogen bonding. The other reason is that the 
unique structure of the Au@TiO2 core-shell NPs with 
a large central hollow cavity provided enough space 
for loading the drug. Thus, the distributed DOX 
molecules could be retained and kept in the Au@TiO2 
carriers to form DOX-loaded Au@TiO2 NPs.  
Synthesis of 
P(CitAPDMAEMA@Au@TiO2@DOX NPs 
As mentioned previously, it is desirable to 
develop high-performance biocompatible anticancer 
agents for cancer treatment, it is necessary to cap or 
switch nanocarriers with porous structures [39]. In 
light of that, the smart pH-sensitive polymer 
P(CitAPDMAEMA) was synthesized [29], as shown in 
Figure 2D. Characterization of these materials was 
shown in Figure S5. P(CitAPDMAEMA) was coated 
to the surface of Au@TiO2@DOX NPs, through a 
physicochemical interactions, such as π-π stacking, 
hydrophobic and electrostatic interactions. The Four-
ier transform infrared (FT-IR) spectra (Figure S6) of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs confirmed 
the efficient surface modification of P(CitAPDMAE 
MA) on the Au@TiO2@DOX NPs [39]. The resultant 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs showed no 
remarkable changes in morphology (Figure S7A) as 
compared to Au@TiO2 NPs. Compared to Au@TiO2 
NPs, the larger diameter of P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs was likely due to the presence of 
P(CitAPDMAEMA) loaded on the surface of the Au@ 
TiO2@DOX NPs (Figure S7B). As illustrated in Figure 
S8A, the P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
exhibited high stability in phosphate buffered 
solution (PBS), fetal bovine serum (FBS), and 
Dulbecco’s modified Eagle medium (DMEM). 
The P(CitAPDMAEMA) content in the P(CitAP 
DMAEMA)@Au@TiO2@DOX NPs was evaluated by 
thermal gravimetric analysis (TGA) (Figure 2E). The 
different weight loss between the P(CitAPDMAEMA) 
@Au@TiO2@DOX NPs and the Au@TiO2@DOX NPs 
at 700 °C indicated that the P(CitAPDMAEMA) 
grafting amount was about 18.4%. Full nitrogen 
adsorption isotherms (Figure S8B) were observed in 
order to obtain information about the specific surface 
areas of the P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs. The BET surface area and the total pore volume 
of the P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
found to be 9.34 m2/g and 0.112 cm3/g, respectively, 
which were smaller than those of the Au@TiO2@DOX 
NPs (41.17 m2/g and 0.674 cm3/g, respectively). These 
results indicated that P(CitAPDMAEMA)@Au@TiO2 
@DOX NPs not only showed a considerable absence 
of porosity but also had important pore blocking 
because of the valve-like function of P(CitAPDMAE 
MA).  
 
 
Figure 2. (A) UV-vis and (B) fluorescence spectra of Au@TiO2 core-shell NPs, DOX, and Au@TiO2@DOX NPs. (C) Quantification of DOX loading at different DOX: 
Au@TiO2 core-shell NPs ratios. (n = 3, mean ± s.d.) (D) Synthetic route for the preparation of (a) BocAPDMAEMA and (b) P(CitAPDMAEMA). (E) TGA curves of 
Au@TiO2@DOX NPs and P(CitAPDMAEMA)@Au@TiO2@DOX NPs. 
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Figure 3. (A) Temperature curves of P(CitAPDMAEMA)@Au@TiO2@DOX NPs at different concentrations. (B) IR images of water and 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs solutions under 635 nm laser irradiation (2.0 W/cm2, 5 min). (C) Photothermal effect of P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs solution (200 µg/mL) under 635 nm laser irradiation (2.0 W/cm2, 5 min). (D) Linear relationship between time and Ln (θ) obtained from the cooling time of (C). (E) 
Mechanism illustration for the enhanced photodynamic activity of Au@TiO2 core-shell NPs. The hollow structure could increase the optical path through multiple reflections and 
scattering, which enhanced light capturing inside the core-shell NPs and boosts light utilization. (F) EPR spectra (DMPO/·OH) of P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
with or without laser irradiation. (G) Time-based absorption intensity reduction of DPBF. (H) Degradation of citraconic amide of P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
under different pH. (n = 6, mean ± s.d.). 
 
Photothermal Properties of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
Another important property of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs was their 
adjustable photothermal effects. Τhe temperature 
changes in P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
aqueous solutions with different concentrations under 
635 nm laser irradiation at 2.0 W/cm2 were initially 
investigated (Figure 3A-B and Figure S9). The initial 
temperature of water and P(CitAPDMAEMA)@Au@ 
TiO2@DOX solution is 25 °C. The solution tempera-
ture was able to be increased precisely by 32.5 °C (200 
μg/mL). On the contrary, the temperature of pure 
water only increased by 2.8 °C. Therefore, cancer cells 
incubated with P(CitAPDMAEMA)@Au@TiO2@DOX 
(200 μg/mL) could be easily heated to temperatures 
higher than 50 °C within 5 min under laser irradiation 
at 2.0 W/cm2, thereby efficiently eliminating the 
cancer cells [40, 41]. In order to further study the 
photothermal conversion efficiency of P(CitAPDMAE 
MA)@Au@TiO2@DOX, the temperature changes of 
the solution (200 μg/mL, 1.0 mL) under continuous 
635 nm laser irradiation (2.0 W/cm2) as a function of 
time were recorded until the solution reached a stable 
temperature (Figure 3C). According to the results, the 
photothermal conversion efficiency could reach 20.4% 
(Figure 3D). 
Photodynamic Properties of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
A proposed principle for the improved 
photodynamic performance of Au@TiO2 core-shell 
NPs was described in Figure 3E. The LSPR effect of 
AuNPs could extend the optical absorption into the 
red region [42]. Therefore, upon red-light excitation, 
photo-electrons could be produced and transferred 
from the AuNPs to the conduction band of TiO2, 
leaving holes in the AuNPs. The reactive electrons 
combined with oxygen to form superoxide radicals 
(·O2−) and the holes could react with H2O to release 
hydroxyl radicals (·OH), which played important 
roles in PDT. Meanwhile, H2O2 could be easily 
adsorbed on the TiO2 surface and gave rise to surface 
complexes, which extended the photoresponse of TiO2 
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to the red region. The production of ·OH radicals 
showed the appearance of an electron-transfer process 
between the surface complexes and the TiO2 
conduction band under red-light irradiation [35, 43]. 
Consequently, the proposed reaction mechanism of 
H2O2 and TiO2 was as follows (Figure 3E): the H2O2 
molecule was adsorbed onto the TiO2 surface and 
formed surface titanium-(IV) hydrogen peroxide 
complexes (TiIV−OOH), which extended the photo-
response to the visible light region and could be 
activated by visible light. The active surface complex 
(TiIV−OOH)* injected an electron to the conduction 
band of the Au@TiO2 core-shell NPs and generated e− 
and TiIV−·OOH, which might further give rise to 
TiIV-OH and 1/2O2 [44]. Therefore, the elevated 
concentration of O2 was helpful to yield ·O2−, which 
further enhanced the efficacy of PDT. Moreover, the 
conduction band electron further reacted with the 
adsorbed H2O2 and released the ·OH radical on the 
TiO2 surface. These highly reactive groups could be 
helpful to generate ROS on the surface of TiO2 and 
Au. It should be noted that in the core-shell NPs, most 
of the AuNPs surface was exposed to the medium. 
Therefore, both TiO2 and AuNPs could provide plenty 
of active sites to form ROS.  
In addition, to explore the performance of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs in PDT, 
the ROS production capability of P(CitAPDMAEMA) 
@Au@TiO2@DOX NPs were investigated. Electron 
spin resonance (ESR) spectroscopy was applied to 
detect ·OH and ·O2_ generation by using 5,5'-di-
methylpyrroline-1-oxide (DMPO) as a spin trap agent. 
According to the ESR spectrum, P(CitAPDMAEMA) 
@Au@TiO2@DOX NPs proved the characteristics of 
DMPO/·OH (Figure 3F) and DMPO/·OOH adduct 
(Figure S10A), which suggested the release of ·OH 
and ·O2− and agreed with the literature [44]. As a 
comparison, no ·OH and ·O2− generation was detected 
in only DMPO or P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs without laser irradiation. Interestingly, the 
intensity of the signal increased sharply upon 635 nm 
laser irradiation, confirming that P(CitAPDMAEMA) 
@Au@TiO2@DOX NPs could efficiently support the 
conversion of laser energy to chemical energy and 
release ROS for PDT. In order to quantify ROS 
generation, a photochemical method using 1,3- 
diphenylisobenzofuran (DPBF) as ROS probe in 
acetonitrile was employed [45]. In the presence of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs, an obvi-
ous reduction in the absorption concentration of 
DPBF as a function of the irradiation time under 635 
nm laser was observed. While in the control group, a 
slight decrease was shown (Figure 3G) when treated 
only with 635 nm laser, indicating the ability of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs to generate 
ROS under red-light irradiation. Furthermore, the 
ROS probe 2,7-dichlorodihydrofluorescein diacetate 
(H2DCFHDA) could generate green fluorescence after 
being oxidized by ROS, which was used to further 
prove intracellular ROS production under 635 nm 
laser irradiation. As shown in Figure S10B, a very 
weak fluorescence signal was presented for the 
resistant HeLa incubated with P(CitAPDMAEMA)@ 
Au@TiO2@DOX NPs without irradiation. In contrast, 
the cells after irradiated with 635 nm laser exhibited a 
strong green fluorescence, demonstrating the intra-
cellular production of ROS. As a result, P(CitAPD-
MAEMA)@Au@TiO2@DOX NPs could work as a new 
multifunctional theranostic nanoplatform for PTT and 
PDT when irradiated by a single 635 nm laser.  
Hydrolysis of Citraconic Amide of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
Amides are acid labile when they have 
β-carboxylic acid groups, and primary amines can be 
exposed during their degradation. P(CitAPDMAE-
MA)@Au@TiO2 NPs was thought to experience 
conversion from zwitterionic to cationic 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs due to 
citraconic amide degradation in acidic conditions. The 
process gave P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs effective cancer cell targeting ability in acidic 
conditions. An amine-reactive fluorescence dye, 
fluorescamine, which reacts with the primary amine 
to generate fluorescent products [29]. As such, with 
the fluorescamine method, the pH-dependent 
decomposition rate of the citraconic amide of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs could be 
detected by comparing the fluorescence before and 
after incubation. According to the results 
demonstrated in Figure 3H, about 97.2% of polymers 
retained the zwitterionic property in the physiological 
environment (pH 7.4), but they exposed the primary 
amine and quaternary ammonium under the acidic 
conditions, due to the removal of the −COO− group in 
citraconic acid. The surface zeta potential of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs also 
changed after P(CitAPDMAEMA) hydrolysis (Figure 
S11). 
Hemolytic Properties of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
For potential clinical applications, anticancer 
agents should have no detrimental effects on the 
human body. To determine the cytotoxicity of 
anticancer agents that are particularly relevant to the 
intravenous application, hemolysis is a standard 
method [46]. Fresh whole rabbit blood was applied to 
measure the hemotoxicity of P(CitAPDMAEMA), 
DOX, and P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
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(Figure 4A). Among the tested concentrations, few red 
blood cells (RBCs) were lysed, indicating a very low 
hemolytic activity of P(CitAPDMAEMA). Meanwhile, 
no detectable hemolytic activity of P(CitAPDMAE-
MA)@Au@TiO2 NPs on RBCs during the entire 
experimental DOX concentration range was found. It 
should be noted that DOX concentration could decide 
the hemolytic activity of soluble DOX. Hemolysis was 
not measured when the tested concentration of DOX 
below 100 μg/mL, while at 250 μg/mL concentration, 
14.3% hemolysis was detected. These results indicated 
that the P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
were safe for blood-contact usage and held potential 
for intravenous administration.  
pH-dependent Binding of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs to 
HeLa cells 
The zwitterionic biocompatible P(CitAPDMAE-
MA)@Au@TiO2@DOX NPs were thought to change 
into cationic and bind to the surface of cancer cells in 
the acidic condition. The binding of P(CitAPDMAE-
MA)@Au@TiO2@DOX NPs to cancer cells under 
acidic condition was evaluated by confocal laser 
scanning microscopy (CLSM), and HeLa cells were 
applied as the model cancer strain. 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
firstly labeled with DOX and then incubated with 
HeLa cells in PBS with different pH for 1 h. From 
Figure 4B, we could see the strong fluorescence in a 
group of HeLa cells at pH 5.0, while a low fluorescent 
signal was detected in the group at pH 7.4. 
DOX Releasing 
In order to evaluate the properties of 
P(CitAPDMAEMA) as drug release tools, the in vitro 
release of DOX from the P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs was monitored by applying the 
dialysis membrane against PBS. In order to investi-
gate the pH-dependent drug release, the released 
DOX was collected by dialyzing P(CitAPDMAEMA)@ 
Au@TiO2@DOX NPs in PBS with different pHs. After 
24 h, about 27.2% of DOX was released from the 
nanoparticles in pH 5.0, in contrast to 10.4% of DOX 
that was released in pH 7.4 (Figure 4C). Next, it was 
investigated whether red light-induced photothermal 
heating could also induce DOX release. 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs in PBS (pH 
5.0 or 7.4) were irradiated by 635 nm laser at 2.0 
W/cm2 for 5 min at different time points. As 
compared to the DOX amount released in dark 
without laser irradiation, red light-stimulus 
dramatically increased the DOX release. Besides, with 
the same laser irradiation, the DOX release seemed to 
be more apparent in the lower pH environment 
compared to that in the physiological pH condition. 
These results indicated that the P(CitAPDMAEMA) 
molecules could be effectively applied as tools to 
instantly turn on/off the drug release, controlled by 
an environmental pH and red light.  
 
 
Figure 4. (A) Hemolytic rates of the DOX, P(CitAPDMAEMA) and P(CitAPDMAEMA)@Au@TiO2@DOX NPs. (n = 3, mean ± s.d.) (B) pH-dependent interaction between 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs and HeLa cells. Scale bar: 30 μm (C) Drug release profile of P(CitAPDMAEMA)@Au@TiO2@DOX NPs at different conditions (pH 
7.5, pH 5.5, and pH 5.5 +laser irradiation) within 24 h. (n = 3, mean ± s.d.) (D) CLSM images of HeLa cells incubated with free DOX and P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs with or without laser irradiation (L+). Scale bar: 25 μm. (E) Fluorescence images of calcein AM/PI-stained HeLa cells incubated with various media: a) laser only; b) 
P(CitAPDMAEMA) (pH 5.0, cationic therapy); c) P(CitAPDMAEMA)@Au@TiO2@DOX NPs (pH 5.0, cationic therapy/chemotherapy); d) Au@TiO2 core-shell NPs (laser 
irradiation, PTT/PDT; e) Au@TiO2@DOX NPs (laser irradiation, chemotherapy/PTT/PDT); f) P(CitAPDMAEMA)@Au@TiO2@DOX NPs (ationic therapy /chemotherapy/ 
PTT/PDT). Scale bar: 100 μm (F) Cytotoxicity of HeLa cells after different treatments. (n = 6, mean ± s.d.). 
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In addition, it was examined whether the 
red-light induced drug release action of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs also exists 
inside cells [47]. Due to the fluorescence quenching of 
DOX after loading on the nano-carriers, reoccurrence 
of the DOX fluorescence could become an indicator 
for drug release. As shown in the CLSM images 
(Figure 4D), no dramatic discrepancy was detected in 
free DOX-treated cells after laser irradiation, and the 
drug molecules were evenly dispersed in the 
cytoplasm and nuclei. By comparison, obvious 
improved DOX fluorescence was detected in cells 
incubated with P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs after laser irradiation, suggesting DOX was 
release from the nano-carriers. Analysis by ImageJ 
software on LSCM images disclosed the quantitative 
evidence that NIR laser irradiation promoted drug 
release from P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs in cells (Figure S12A). These results collectively 
proved that red-light irradiation could effectively 
trigger intracellular drug release from P(CitAPDMA-
EMA)@Au@TiO2@DOX NPs. 
Cell Toxicity  
The in vitro cytotoxicity of as-prepared 
P(CitAPDMAEMA) and Au@TiO2 core-shell NPs 
were then evaluated with HeLa cells as a model by 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazol
ium bromide (MTT) assay (Figure S12B). No obvious 
cytotoxicity to the P(CitAPDMAEMA) or Au@TiO2 
core-shell NPs-transfected HeLa cells was observed as 
the P(CitAPDMAEMA) and Au@TiO2 core-shell NPs 
concentration ranged from 50 to 150 μg/mL, while a 
slight reduction of cell viability appeared at extremely 
high concentrations (200 μg/mL), indicating their 
good biocompatibility.  
Subsequently, the efficacy of the cationic 
therapy/chemotherapy/PDT/PTT and the cytotoxi-
city of the produced P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs were investigated in vitro. Normal and dead 
cells were determined by applying calcein AM (green) 
and PI (red) staining, respectively. In the laser-only 
(2.0 W/cm2) groups, no dead cells was observed, due 
to green fluorescence displayed by all cells (Figure 
4E,a). This phenomenon showed the inability of the 
heat generated from pure water under irradiation to 
cause cancer cell death. Since P(CitAPDMAEMA) is 
able to bind to HeLa cells and can be converted to 
cationic P(CitAPDMAEMA) in the acidic environ-
ment, it was thought to obtain anticancer efficacy. In 
Figure S13, it was observed that P(CitAPDMAEMA) 
pretreated at pH 7.4, but did not show any effect on 
the growth of the HeLa cells, which was due to its 
zwitterionic nature at neutral pH. However, in the 
case of P(CitAPDMAEMA) pretreated at pH 5.0 
(Figure 4E,b), the growth of the HeLa cells was 
obviously restrained. This result could be explained 
that P(CitAPDMAEMA) effectively absorbed the 
negative charge on the membrane of HeLa cells in the 
acidic environment, which inhibited the growth and 
metastasis of HeLa cells. Meanwhile, some cells got 
damage after incubating with 200 μg/mL Au@TiO2@ 
DOX NPs (Figure 4E,c) because of the release of DOX. 
After laser irradiation at 2.0 W/cm2 and incubation 
with 200 μg/mL Au@TiO2 core-shell NPs (Figure 
4E,d) and Au@TiO2@DOX NPs (Figure 4E,e), most of 
the cells were destroyed. On the contrary, after laser 
irradiation at 2.0 W/cm2 and incubation with 200 
μg/mL P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
(Figure 4E,f), almost all cells were killed, as 
demonstrated by the obtained intense homogeneous 
red fluorescence. The result was attributed to the fact 
that P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
able to simultaneously release DOX at high power 
doses, converting back to cationic P(CitAPDMAE-
MA), and generate ·OH/·O2-, and produce heat to 
efficiently kill cells by combined cationic therapy/ 
chemotherapy/PDT/PTT using a single red laser. 
Moreover, the cationic therapy/chemotherapy/PDT/ 
PTT efficacy of the P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs was quantitatively assessed by the MTT 
assay. Among cationic therapy, chemotherapy, 
PDT/PTT, and chemotherapy/PDT/PTT groups, cell 
viability decreased with the increasing dose of the 
sample, while some cells remained alive even at a 
high sample concentration (200 μg/mL). However, in 
the cationic therapy/chemotherapy/PDT/PTT group, 
a mortality rate of ~98% was obtained, indicating that 
the simultaneous effects of cationic therapy/chemo-
therapy/PDT/PTT were able to effectively kill cancer 
cells (Figure 4F). These results agreed with the calcein 
AM and PI staining findings. 
MR Imaging 
It is known that the carboxyl and hydroxyl 
groups can easily chelate different kinds of metal ions, 
such as Cu2+, Mn2+, and Fe3+ [47, 48]. Among these 
metal ions, Mn2+ has been widely utilizing as a 
contrast agent for MRI. Based on the present system, 
Mn2+ was successfully loaded on P(CitAPDMAE-
MA)@Au@TiO2@DOX NPs by intrinsically chelating 
with carboxyl and hydroxyl groups on the surface of 
NPs. Interestingly, the obtained Mn@P(CitAPDMA-
EMA)@Au@TiO2@DOX NPs demonstrated a signifi-
cant intensity-dependent brightening function under 
T1-weighted MRI (inset of Figure 5A), as well as a 
darkening function under T2-weighted MRI (inset of 
Figure 5B). The r1 and r2 relaxivities of the 
Mn@P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
detected at 11.1 mM-1s-1 and 40.8 mM-1s-1, respectively.  
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Figure 5. The (A) T1/(B) T2 relaxation rates and T1/T2-MR images (insets) of n@P(CitAPDMAEMA)@Au@TiO2@DOX NPs solutions with different Mn2+ concentrations. (C) 
In vivo T1/T2-MR images of HeLa-tumor-bearing mice taken 0 h and 24 h post i.v. injection with Mn@P(CitAPDMAEMA)@Au@TiO2@DOX NPs. (D) The fluorescence images 
of HeLa-tumor-bearing mice after i.v. injected with P(CitAPDMAEMA)@Au@TiO2@DOX NPs. The tissues were exploited for ex vivo fluorescence images after 24 h i.v. 
injection. (E) Blood circulation of Mn@P(CitAPDMAEMA)@Au@TiO2@DOX NPs after i.v. injection (n = 5, mean ± s.d.). (F) IR thermal images of HeLa-tumor-bearing mice 
injected with (a) Au@TiO2 core-shell NPs, (b) Au@TiO2@DOX NPs, (c) P(CitAPDMAEMA)@Au@TiO2@DOX NPs, and (d) PBS under 635 nm laser irradiation (2.0 W/cm2, 
5 min). 
 
Therefore, the developed Mn@P(CitAPDMA 
EMA)@Au@TiO2@DOX NPs could be applied as a 
contrast agent for both T1-weighted and T2-weighted 
MRI. Furthermore, in vivo MRI was applied on mice. 
Mice bearing HeLa tumors were initially 
intravenously (i.v.) injected with Mn@P(CitAPDM 
AEMA)@Au@TiO2@DOX NPs and then imaged on a 
3.0 T MRI system. Significant brightening or 
darkening effects were observed in the tumor region 
of mice compared with the pre-injected image (Figure 
5C), suggesting high tumor accumulation of those 
NPs after systemic administration. Furthermore, the 
stronger T1- and T2-weighted MRI signal could be 
observed in the tumor region at 24 h post-injection. 
ImageJ was used to measure the region-of-interest 
(ROI) quantification (Figure S14) which further 
confirmed the enhancement of signal intensity in the 
tumor region after i.v. injection of Mn@P 
(CitAPDMAEMA)@Au@TiO2@DOX NPs. These 
results indicated that the effective tumor 
accumulation of Mn@P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs via EPR effect and blood circulation. 
Fluorescent Imaging 
The whole-body fluorescence imaging was used 
to detect the biodistribution of DOX in HeLa 
tumor-bearing mice at specific time points following 
intravenous injection of P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs (5 mg/kg). As shown in Figure 5D, 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs could 
spread into the body of mice. Interestingly, the drug 
delivery nanosystem based on the 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs was 
accumulated in the tumor at 24 h. This result was 
validated by the quantitative detection of DOX 
intensity in the normal tissue and the tumor regions 
(Figure S15). It was speculated that 
P(CitAPDMAEMA)@Au@TiO2 NPs were captured by 
the liver, spleen, and lung tissues, which prolonged 
the blood-circulation lifetime. As a result, this 
progress increased the efficiency of the 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs to 
recognize and gather at the tumor site [49]. In 
particular, the gathering of P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs in the heart decreased, indicating that 
the nanosystem could decrease cardiac muscle 
toxicity caused by DOX. These findings showed that 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs were able 
to recognize the tumor, accumulate in the tumor, and 
decrease the side effects of DOX. 
Blood Circulation and Biodistribution 
Prior to combination therapy, the in vivo 
behavior of the P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs were examined. Female Balb/c mice were i.v. 
injected with P(CitAPDMAEMA)@Au@TiO2@DOX 
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NPs (5 mg/kg, 200 μL). Blood was collected from the 
mice at every time point. After being dispersed in 
lysis buffer and extracted with HCl/isopropanol, 
DOX was measured by fluorescence in order to assess 
its intensity in the blood [47]. As seen in Figure 5E, the 
signals of DOX gradually decreased over time 
following a two-compartment model, where the first 
(t1/2(α)) and second (t1/2(β)) phases of circulation 
half-lives were calculated to be 1.92 ± 0.24 h and 9.86 ± 
0.52 h, respectively. Furthermore, half of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
rapidly excreted through the urine and feces route 24 
h after injection due to their nanoscale (Figure S16). 
After 24 h intravenous injection, a large part of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs appeared 
in the liver and kidney because of the 
reticuloendothelial system clearance. Around 23.7% 
of the P(CitAPDMAEMA)@Au@TiO2@DOX NPs were 
accumulated into the tumor through the EPR effect 
and the cationic targeting effect (Figure S17). It could 
also modify the targeted ligands to improve its 
accumulation efficiency. P(CitAPDMAEMA)@Au@ 
TiO2@DOX NPs could be not only passively target the 
tumor tissue, but also evaluate the tumor 
site/dimension/morphology by fluorescent/infrared 
thermal/MR treble-modal imaging which was able to 
guide the simultaneous PTT and PDT. 
In Vivo Photothermal Imaging 
In the light of good photothermal conversion of 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs, we 
evaluated in vivo photothermal efficiency in the tumor 
model. Female Balb/c mice were i.v. injected with 
Au@TiO2 core-shell NPs, Au@TiO2@DOX NPs, P(Cit-
APDMAEMA)@Au@TiO2@DOX NPs, and PBS. After 
6 h, tumor regions of mice were irradiated by 635 nm 
laser with a power density of 2.0 W/cm2 for 5 min. 
The change of temperature during irradiation was 
detected by an IR thermal camera (Figure 5F and 
Figure S18). The temperatures of tumor in the mice 
injected with Au@TiO2@DOX NPs, Au@TiO2 
core-shell NPs, and P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs demonstrated a rapid increase and then 
maintained at 54 °C during 635 nm laser irradiation. 
In contrast, little change was measured in the tumor 
temperature of the mice injected with 
P(CitAPDMAEMA)@Au@TiO2 NPs and PBS under 
635 nm laser irradiation using the same parameters.  
In Vivo Combined Therapy 
Based on the mentioned in vivo imaging results, 
in vivo cancer treatment with P(CitAPDMAEMA)@ 
Au@TiO2@DOX NPs was carried out (Scheme 1). 
Female Balb/c mice were subcutaneously injected 
into their backs with 1×106 HeLa cells. After one week, 
the tumors grew to 60 mm3 and the mice were divided 
into 6 groups: P(CitAPDMAEMA)@Au@TiO2 NPs (1), 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs (2), PBS 
(plus Laser) (3), Au@TiO2@DOX NPs (plus Laser) (4), 
Au@TiO2 core-shell NPs (plus Laser) (5), and 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs (plus 
Laser) (6). The drug and drug-loaded NPs were i.v. 
injected into each mouse through the tail vein. After 
the treatment by laser, the tumor volume was 
measured by a digital caliper every two days for a 
total of two weeks (Figure 6A-B). The combination 
therapy group of the P(CitAPDMAEMA)@Au@TiO2@ 
DOX NPs with laser irradiation, demonstrated an 
obvious inhibition of tumor growth. The Au@TiO2 
core-shell NPs and Au@TiO2@DOX NPs with laser 
irradiation presented a small inhibitory function 
during the early days, but grew normally later. The 
P(CitAPDMAEMA)@Au@TiO2 NPs and P(CitAPDM 
AEMA)@Au@TiO2@DOX NPs treatment groups 
seemed to have a minimal influence on tumor growth. 
These results were also confirmed by representative 
tumor images (Figure 6C) at day 14. Slices of tumors 
stained with hematoxylin and eosin (HE) and TUNEL 
staining (Figure 6D) were obtained, in order to further 
assess the therapeutic function of the various 
treatments. It was shown that the combination treat-
ment group P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs with laser irradiation showed the most effective 
damage on most of the tumor cells, while the other 
five groups depicted little or no damage on tumor 
cells, which had normal membrane morphology and 
nuclear structures.  
In order to investigate whether these treatments 
would induce toxicity, the body weight of the mice 
was monitored (Figure S19) and histology of organ 
samples including lung, liver, spleen, kidney, and 
heart was performed (Figure S20). The body weight of 
the mice in the treated groups was about the same as 
those in the control group. No loss of body weight or 
other serious toxic effects were observed. Further-
more, the histological analysis did not reveal any 
serious irreversible pathological alterations or injuries 
in the organs of the mice of all groups. Moreover, the 
toxicity of the P(CitAPDMAEMA)@Au@TiO2@DOX 
NPs with laser irradiation was detected by blood 
biochemical analysis. As can be seen in Figure 6E-F, 
the P(CitAPDMAEMA)@Au@TiO2@DOX NPs with 
laser irradiation group demonstrated no apparent 
increase in lactate dehydrogenase (LDH) and creatine 
kinase (CK) levels, which were necessary parameters 
for heart function. In addition, the analysis of liver 
function (Figure 6G-H) [aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT)] and 
kidney function (Figure 6J-I) [uric acid (UA) and 
creatinine] parameters did not show any damage to 
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liver and kidney in the mice treated with 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs with laser 
irradiation. This phenomenon suggested that the 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs combina-
tion treatment did not induce any toxicity. All results 
above clearly showed that the P(CitAPDMAEMA)@ 
Au@TiO2@DOX NPs could serve as powerful in vivo 
anticancer agents. 
Conclusions 
In conclusion, we have successfully designed 
and constructed a multifunctional nanohybrid for 
imaging-guided combination treatment of cancer. The 
resultant P(CitAPDMAEMA)@Au@TiO2@DOX NPs 
possessed the following features: (1) rapid binding to 
cancer cells under acidic conditions; (2) high 
photothermal conversion efficiency under 635 nm 
laser irradiation; (3) efficient ROS release upon 635 
nm laser irradiation; (4) induced DOX release by 
external red-light and at intracellular pH values. In 
addition, those NPs possessed obvious contrasts in 
MRI after the chelation with Mn2+. An 
imaging-guided cancer therapy, which combined 
with those functional parts, was shown in mouse 
tumor model experiments. The cationic therapy/ 
chemotherapy/PTT/PDT delivered by the 
 
 
Figure 6. (A) Tumor growth curves for mice with various treatment. (n = 5, mean ± s.d., **P<0.01, and ***P<0.001). (B) The digital photographs of mice 14th days with various 
treatments. (C) Representative photographs of the excised tumors 14th days with various treatments. (up to bottom: PBS (L+), P(CitAPDMAEMA)@Au@TiO2 NPs, 
P(CitAPDMAEMA)@Au@TiO2@DOX NPs, Au@TiO2 core-shell NPs (L+), Au@TiO2@DOX NPs (L+), and P(CitAPDMAEMA)@Au@TiO2@DOX NPs (L+)). (D) TUNEL 
and HE staining of tumor slices collected from different mice groups after 14 days treatment. (E−J) Blood biochemistry analysis (LDH, CK, AST, ALT, UA, and Creatinine) of the 
different mice groups after 14 days treatment. (n = 5, mean ± s.d.). 
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P(CitAPDMAEMA)@Au@TiO2@DOX NPs showed a 
significant combined effect in destructing tumors 
using. Moreover, the tiny size of the nanoparticles 
allowed for partial renal clearance and high tumor 
uptake in vivo, making the theranostic agent a 
promising candidate for future clinical translation. 
Experimental Section 
Chemicals 
2-(Dimethylamino)ethyl methacrylate (DMAE-
MA, 98%), citraconic anhydride (Cit, 98%), 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT, 98%) and 4-cyanopentanoic acid 
dithiobenzoate (CPADB, 98%) were purchased from 
Sinopharm Chemical Reagent CO, Ltd., China. 
Doxorubicin (DOX) were purchased from Tianjin 
Biolite Biotech Co., Ltd. The dialysis tube membrane 
with molecular weight cutoff (MWCO) of 1000 was 
purchased from Peg Bio, Suzhou, China. All aqueous 
solution used in experiment was deionized water (DI, 
18.2 MΩ·cm) obtained from Milli-Q water purification 
system.  
Instruments and characterization 
The infrared spectrum was performed on a 
Nexus 670 FTIR type (Nicolet). The X-ray diffraction 
(XRD) analysis was performed using a D/Max 
2500V/PC diffractometer (Rigaku Corporation, 
Japan). UV-Vis spectroscopy measurements were 
performed on a Cary 5000 UV-Vis-NIR spectrometer 
(Varian). The surface composition and element 
analysis of the samples were recorded using X-ray 
photoelectron spectroscopy (XPS, EscaLab-250, 
Thermo, USA). The hydrodynamic size and 
zeta-potential were measured on a Malvern ZEN 3600 
Zetasizer (Malvern Instruments, UK). The 
transmission electron microscopy (TEM) images were 
acquired on a JEM-2100F TEM. The fluorescent 
images of cells were acquired by Confocal Scanning 
Laser Microscope (CSLM, TI-E-A1R, Nikon, Japan). 
The infrared thermal images were recorded with a 
PTT monitoring system MG33 (Shanghai Magnity 
Electronics Co. Ltd.). The methods used for material 
characterization are displayed in the experimental 
section of the supporting information. 
Supplementary Material  
Supplementary experimental section, schemes and 
figures. http://www.thno.org/v09p5035s1.pdf  
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